- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05846724
Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (PULSAR)
A Phase II Single-arm Study of Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (CKS)
Phase II study of Pembrolizumab plus Lenvatinib in relapsed/refractory Classic Kaposi Sarcoma (CKS). After a screening phase of up to 28 days, each participant will receive study intervention of pembrolizumab plus lenvatinib until reaching a discontinuation criterion: disease progression; unacceptable adverse event(s) (AEs); intercurrent illness that prevents further administration of treatment; participant withdraws consent; pregnancy of participant; non-compliance with study intervention or procedure requirements; or administrative reasons requiring cessation of treatment.
After the end of treatment, each participant will be followed for the occurrence of AEs and spontaneously reported pregnancy.
Participants who discontinue for reasons other than PD will have post-treatment follow-up for disease status until PD is documented clinically by a team of committed dermatologists, and/or radiographically per RECIST 1.1, a non-study anticancer treatment is initiated, consent is withdrawn, or the participant becomes lost to follow-up.
All participants will be followed for overall survival (OS) until death, withdrawal of consent,lost to follow-up, or the end of the study. The end of the study will be when the last participant completes the last study-related telephone call or visit,withdraws from the study, or is lost to follow-up.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a histologically confirmed diagnosis of classic (or endemic) KS
- Progression or inadequate response to at least one prior systemic chemotherapy
- Presence of measurable disease by PET-CT scan and/or dermatological examination
- KS with at least 10 cutaneous and/or mucosal lesions, or involving more than one limb segment or with involvement >3% body surface
- KS with at least 4 lesions ≥ 5mm
- KS with at least 1 superficial lesion willing to provide tissue from cutaneous and/or mucosal biopsy at baseline
- At least 4 weeks washout for all KS specific therapies including chemotherapy (both systemic and intralesional) and radiotherapy
- Be ≥ 18 years of age at the time of signing informed consent
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Have adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization.
Exclusion Criteria:
- Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies detected at screening).
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
- Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis not requiring systemic treatment are permitted to enroll.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
|
single-arm study of pembrolizumab plus lenvatinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) of pembrolizumab with lenvatinib in pre-treated recurrent CKS
Time Frame: 6 months
|
the combination of pembrolizumab and lenvatinib has superior ORR, as compared to cytotoxic chemotherapy by literature data.
ORR defined as a confirmed complete response (CR) or partial response (PR).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR) in patients with pre-treated recurrent CKS receiving pembrolizumab with lenvatinib
Time Frame: 6 months
|
The combination of pembrolizumab and lenvatinib provides superior DOR, as compared to cytotoxic chemotherapy by literature data.
|
6 months
|
Overall Survival in patients receiving pembrolizumab and lenvatinib
Time Frame: 6 months
|
The combination of pembrolizumab and lenvatinib has superior OS, as compared to cytotoxic chemotherapy by literature data.
|
6 months
|
The mean change from baseline in the global health status/quality of life (QoL), and physical functioning for the combinations of pembrolizumab and lenvatinib
Time Frame: 6 months
|
Score for the following patient-reported outcomes (PROs) scales/items: global health status/QoL (EORTC QLQ-C30items 29 and 30), and physical functioning (EORTC QLQ-C30 items 1-5).
|
6 months
|
Safety and tolerability for the combination of pembrolizumab and lenvatinib.
Time Frame: 6 months
|
Adverse Events (AEs) incidence and study intervention discontinuation due to AEs
|
6 months
|
Progression Free Survival (PFS) of patients with pre-treated recurrent CKS receiving pembrolizumab with lenvatinib.
Time Frame: 6 months
|
The combination of pembrolizumab and lenvatinib has superior PFS, as compared to cytotoxic chemotherapy by literature data.
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- DNA Virus Infections
- Herpesviridae Infections
- Neoplasms, Vascular Tissue
- Sarcoma
- Sarcoma, Kaposi
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Lenvatinib
Other Study ID Numbers
- MK-3475-B60
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Classic Kaposi Sarcoma
-
Assistance Publique - Hôpitaux de ParisUnknownKaposi' s Sarcoma | Classic Kaposi' s Sarcoma | Endemic Kaposi' s Sarcoma | Lymph Angio ProliferationsFrance
-
National Cancer Institute (NCI)National Institute of Allergy and Infectious Diseases (NIAID)WithdrawnClassic Kaposi Sarcoma | AIDS-related Kaposi Sarcoma
-
Alona ZerBristol-Myers SquibbUnknown
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, Los Angeles; Montefiore... and other collaboratorsCompletedSkin Kaposi Sarcoma | Recurrent Kaposi SarcomaUnited States, Uganda, South Africa
-
National Cancer Institute (NCI)RecruitingHIV Infection | Advanced Malignant Solid Neoplasm | Kaposi Sarcoma | Lung Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Anal Carcinoma | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin LymphomaUnited States, Australia
-
National Cancer Institute (NCI)CompletedAIDS-related Kaposi Sarcoma | Recurrent Kaposi SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
National Cancer Institute (NCI)CompletedHIV Infection | Recurrent Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCWithdrawnHIV Infection | AIDS-related Kaposi Sarcoma | Recurrent Kaposi Sarcoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Cancer Immunotherapy Trials Network (CITN)TerminatedHIV Infection | Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
Clinical Trials on Pembrolizumab + Lenvatinib
-
Peking Union Medical College HospitalCompletedCholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant PrimaryChina
-
National University Hospital, SingaporeRecruitingAdenocarcinomas | Recurrent GynecologicalSingapore
-
Tianjin Medical University Second HospitalRecruiting
-
Eisai Co., Ltd.Merck Sharp & Dohme LLCCompleted
-
University College, LondonMerck Sharp & Dohme LLCRecruitingHepatocellular CarcinomaUnited Kingdom
-
Peking Union Medical College HospitalRecruitingBiliary Tract Neoplasms ImmunotherapyChina
-
Saint Petersburg State University, RussiaRecruitingAnaplastic Thyroid CancerRussian Federation
-
Shanghai Zhongshan HospitalActive, not recruitingCarcinoma, HepatocellularChina
-
Peking University Cancer Hospital & InstituteNot yet recruitingMucosal Melanoma | Neoadjuvant TreatmentChina
-
Abramson Cancer Center at Penn MedicineMerck Sharp & Dohme LLCRecruitingRenal Cell CarcinomaUnited States